百奥泰：托珠单抗皮下制剂已完成临床试验

Core Viewpoint - The company Baiotai has completed clinical trials for its subcutaneous formulation of Tocilizumab and is actively preparing for the submission of relevant applications [2] Group 1 - The subcutaneous formulation of Tocilizumab has successfully completed clinical trials [2] - The company is currently advancing preparations for application submission [2]